^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + molibresib (GSK525762) (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
Published date:
12/16/2020
Excerpt:
Our results confirmed a synergistic efficacy between I-BET762 and Talazoparib in MYCs-amplified SCLC cells.
DOI:
10.3390/ijms21249595
